comparemela.com

Latest Breaking News On - Nasdaq cnta - Page 5 : comparemela.com

Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 4.4%

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) dropped 4.4% during trading on Thursday . The stock traded as low as $6.02 and last traded at $6.08. Approximately 9,006 shares traded hands during mid-day trading, a decline of 94% from the average daily volume of 155,927 shares. The stock had previously closed at […]

Harris-rotman
Jpmorgan-chase-co
Institutional-trading-of-centessa-pharmaceuticals
News-ratings-for-centessa-pharmaceuticals-daily
Centessa-pharmaceuticals
Nasdaq
Renaissance-technologies
Securities-exchange-commission
Goldman-sachs-group-inc
Susquehanna-international-group
Goldman-sachs-group
Insider-activity-at-centessa-pharmaceuticals

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Short Interest Down 29.7% in August

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) saw a large drop in short interest in the month of August. As of August 31st, there was short interest totalling 1,300,000 shares, a drop of 29.7% from the August 15th total of 1,850,000 shares. Approximately 2.3% of the shares of the company are sold short. Based […]

Centessa-pharmaceuticals-price-performance
Institutional-investors-weigh-in-on-centessa-pharmaceuticals
Nasdaq
News-ratings-for-centessa-pharmaceuticals-daily
Barclays-plc
Centessa-pharmaceuticals
Goldman-sachs-group
Susquehanna-international-group
Renaissance-technologies
Goldman-sachs-group-inc
Jpmorgan-chase-co

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $8.50 Average PT from Analysts

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the […]

Analyst-recommendations-for-centessa-pharmaceuticals
News-ratings-for-centessa-pharmaceuticals-daily
Goldman-sachs-group
Nasdaq
Institutional-trading-of-centessa-pharmaceuticals
Centessa-pharmaceuticals-company-profile
Affinity-asset-advisors
Centessa-pharmaceuticals
Centessa-pharmaceuticals-stock
Get-free-report
Marketbeat-ratings

Centessa Pharmaceuticals to Present Preclinical Data for

Oral presentation to include preclinical profile for ORX750, Centessa’s first orexin agonist development candidate for the treatment of narcolepsy and.

London
City-of
United-kingdom
Boston
Massachusetts
United-states
Russia
Rio-de-janeiro
Estado-do-rio
Brazil
Ukraine
David-grainger

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Given Consensus Rating of "Moderate Buy" by Brokerages

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) has earned an average rating of “Moderate Buy” from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on […]

Tial-bush
Antoine-yver
Goldman-sachs-group-inc
Centessa-pharmaceuticals
Susquehanna-international-group
Analyst-recommendations-for-centessa-pharmaceuticals
Insider-activity-at-centessa-pharmaceuticals
Centessa-pharmaceuticals-company-profile
Jpmorgan-chase-co
Barclays-plc
Goldman-sachs-group
Nasdaq

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.